Gentamycin Sulfate Injection

This product is an aminoglycoside antibiotic. It has good antibacterial effects on various Gram-negative and Gram-positive bacteria, and has good antibacterial effects on various Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Pseudomonas aeruginosa. Neisseria and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella, Yersinia pestis, Acinetobacter and Campylobacter fetus. It has a good antibacterial effect on about 80% of methicillin-sensitive strains of Staphylococcus (including Staphylococcus aureus and coagulase-negative Staphylococci), but methicillin-resistant strains are mostly resistant to this product. It has a poor effect on Streptococcus and Streptococcus pneumoniae, and Enterococcus is mostly resistant to this product. When this product is used in combination with beta-lactams, most of them can obtain a synergistic antibacterial effect. The mechanism of action of this product is to bind to the 30S subunit of bacterial ribosomes and inhibit the synthesis of bacterial proteins. In recent years, the number of gram-negative bacteria resistant to gentamicin has increased significantly.

The main ingredient of this product is gentamicin sulfate, which is a multi-component antibiotic containing components such as C1, C1a, C2a, and C2.

It is used for sepsis, respiratory tract infection, biliary tract infection, purulent peritonitis, intracranial infection, urinary tract infection and bacillary dysentery caused by Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Shigella dysenteriae, Klebsiella, Proteus and other sensitive bacteria.

1. For adults, intramuscular injection or dilution after intravenous drip, 80 mg (80,000 units) at a time, or 1-1.7 mg/kg per body weight, once every 8 hours; or 5 mg/kg once, once every 24 hours. The course of treatment is 7 to 14 days. When intravenously dripping, add a single dose to 50-200 ml of 0.9% sodium chloride injection or 5% glucose injection. The amount of liquid added during intravenous drip once a day should be no less than 300 ml, so that the concentration of the drug solution does not exceed 0.1%. The solution should be dripped slowly within 30 to 60 minutes to avoid neuromuscular blocking effects. 2. For children, intramuscular injection or dilution after intravenous drip, 2.5 mg/kg once, once every 12 hours; or 1.7 mg/kg once, once every 8 hours. The course of treatment is 7 to 14 days, and blood drug concentrations should be monitored as much as possible during this period, especially for newborns or infants. 3 The dosage for intrathecal and intraventricular administration is 4-8 mg for adults and 1-2 mg for children (over 3 months old), once every 2-3 days. When injecting, dilute the drug solution to a concentration not exceeding 0.2%, draw it into a 5ml or 10ml sterile syringe, and after lumbar puncture, allow a considerable amount of cerebrospinal fluid to flow into the syringe first, and then push while drawing, and slowly inject all the drug solution within 3-5 minutes. 4 Dosage for patients with renal impairment: once every 8 hours for patients with normal renal function, the normal dose is 1-1.7 mg/kg at a time. When the creatinine clearance rate is 10-50ml/min, once every 12 hours, 30-70% of the normal dose; when the creatinine clearance rate is <10ml/min, 20-30% of the normal dose is given every 24-48 hours.

1. Ototoxic reactions such as hearing loss, tinnitus or fullness in the ears may occur during medication. When vestibular function is affected, unsteady gait and dizziness may occur. Nephrotoxic reactions such as hematuria, significantly reduced urination frequency or urine volume, loss of appetite, and extreme thirst may also occur. Those with a lower incidence include dyspnea, drowsiness, weakness, etc. caused by neuromuscular blockade or nephrotoxicity. Occasionally, there may be rash, nausea, vomiting, decreased liver function, leukopenia, granulocytopenia, anemia, hypotension, etc. 2. A small number of patients may experience ototoxic symptoms such as hearing loss, tinnitus or fullness in the ears after discontinuation of the drug, which should be paid attention to. 3. Systemic administration combined with intrathecal injection may cause leg cramps, rash, fever, and systemic spasms.

Patients who are allergic to this product or other aminoglycosides are contraindicated.

1. When used in combination with other aminoglycosides or when used topically or systemically successively, it may increase the possibility of producing ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. When used in combination with neuromuscular blockers, it may aggravate neuromuscular blocking effects, leading to symptoms such as muscle weakness and respiratory depression. 3. When used in combination with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), or when used topically or systemically successively, it may increase ototoxicity and nephrotoxicity. 4. When used topically or systemically with cephalothin or cefazolin, it may increase nephrotoxicity. 5. When used in combination with polymyxin injections or when used topically or systemically successively, it may increase nephrotoxicity and neuromuscular blocking effects. 6. Other nephrotoxic and ototoxic drugs should not be used in combination with this product or when used topically successively, so as not to aggravate nephrotoxicity or ototoxicity. 7. When aminoglycosides and beta-lactams (cephalosporins and penicillins) are mixed, they may lead to mutual inactivation. When this product is used in combination with the above-mentioned antibiotics, it must be dripped in separate bottles. This product should not be infused in the same bottle with other drugs.

Keep tightly closed in a cool, dark place.

1ml: 20,000 units

Guosen Pharmaceutical Co., Ltd.

• Founded in:

  2005-02-22

• Address:

  No. 669, Changjiang West Road, High-tech Zone, Hefei City, Anhui Province

• Tax NO.:

  91340000771133813K

• Registered Funds:

  89.66 million yuan

• Email:

  Log in to view